The advent of GLP-1RAs has added a notable dimension to T2D management, allowing a greater number of patients to reach their glycemic targets than was previously achieved with conventional medicines (7), and these agents are now recommended before insulin for treatment of T2D (8). The gene discussed is INS; the disease is type 2 diabetes mellitus.